Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05754281 · ClinicalTrials.gov registry record
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
A clinical trial of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by Joslin Diabetes Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05754281: Recruiting study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by Joslin Diabetes Center.
NCT05754281 is a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus that is actively recruiting participants, run by Joslin Diabetes Center. The registered enrollment target is 60 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05754281, a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by Joslin Diabetes Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the accuracy of the Cambridge Medical Technologies, LLC second generation (2nd Gen) LabPatch glucose sensing system compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite. The primary endpoint of this study is the mean absolute relative difference (MARD) for 2nd Gen LabPatch system compared to each of the above mentioned glucose references over a 6 hour outpatient visit.
Primary Outcome
Blood glucose values (mg/dL) from the LabPatch system and reference YSI, One Touch Verio, and FreeStyle Lite will be used to report the mean absolute relative difference (MARD) in Percentage (%).
Conditions Studied
Interventions
- DEVICE 2nd Gen LabPatch Glucose Sensing System
Study Locations (1)
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2026-12-31 |
What NCT05754281 shows while recruiting
NCT05754281 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which 2nd Gen LabPatch Glucose Sensing System is the first listed.
NCT05754281 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05754281 about?
NCT05754281 is a clinical study titled "The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System". The purpose of this study is to evaluate the accuracy of the Cambridge Medical Technologies, LLC second generation (2nd Gen) LabPatch glucose sensing system compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite. The primary end...
What is the current status of trial NCT05754281?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2023-02-03. Estimated completion is 2026-12-31.
What conditions does trial NCT05754281 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT05754281?
The interventions under investigation include: 2nd Gen LabPatch Glucose Sensing System (DEVICE).
Who is sponsoring clinical trial NCT05754281?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05754281 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05754281's enrollment target sits among peer trials
60 72nd of 130 higher than 56 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
RECRUITING
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI